Valuation: Avicanna Inc.

Market Cap 16.13M 11.41M 9.98M 9.2M 8.5M 1.09B 16.4M 110M 43.18M 536M 42.82M 41.89M 1.84B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 15.85M 11.21M 9.8M 9.04M 8.35M 1.07B 16.11M 108M 42.42M 527M 42.08M 41.16M 1.81B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day-4.00%
Current month-4.00%
1 month+9.09%
3 months-20.00%
6 months-47.83%
Current year-46.67%
1 week 0.1
Extreme 0.095
0.13
1 month 0.1
Extreme 0.095
0.14
Current year 0.1
Extreme 0.095
0.24
1 year 0.1
Extreme 0.095
0.31
3 years 0.1
Extreme 0.095
0.6
5 years 0.1
Extreme 0.095
1.01
10 years 0.1
Extreme 0.095
7.4
Manager TitleAgeSince
Sales & Marketing - 2015-04-30
Chief Executive Officer 39 2016-11-25
Director of Finance/CFO - 2025-09-14
Director TitleAgeSince
Chairman 39 2016-11-25
Director/Board Member - 2018-10-21
Director/Board Member - 2025-12-31
Date Insider Type Main position Quantity % Market Cap.
06-17Buy

Chief Financial Officer

-65,079 0.0517%
06-17Option

Founder

75,000 0.0596%
06-17Buy

Director

225,500 0.1793%
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%0.00%-50.00%-60.00% 11.41M
+0.58%+2.06%+3.90%+10.40% 50.73B
-2.22%-1.25%+391.53%+591.38% 39.73B
-0.54%+0.39%+27.67%-3.89% 34.69B
-1.36%+0.35%+19.34%+58.83% 33.21B
+1.21%-4.58%+3.00%+37.03% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+125.61% 15.37B
+0.23%-0.58%+13.80%+19.56% 13.78B
-0.62%-3.09%+11.43%-29.93% 12.85B
Average -0.80%-0.75%+54.12%+83.22% 24.39B
Weighted average by Cap. -0.48%-0.23%+82.74%+126.13%

Financials

2024 2025
Net sales 25.46M 18.01M 15.75M 14.53M 13.42M 1.72B 25.89M 174M 68.16M 846M 67.61M 66.14M 2.91B 25.48M 18.02M 15.76M 14.54M 13.43M 1.72B 25.91M 174M 68.22M 847M 67.66M 66.19M 2.91B
Net income -3.62M -2.56M -2.24M -2.06M -1.91M -244M -3.68M -24.66M -9.69M -120M -9.61M -9.4M -413M -2.76M -1.95M -1.71M -1.57M -1.45M -186M -2.81M -18.81M -7.39M -91.69M -7.33M -7.17M -315M
Net Debt -339K -240K -210K -193K -179K -22.85M -344K -2.31M -907K -11.26M -900K -880K -38.7M -281K -198K -174K -160K -148K -18.93M -285K -1.91M -751K -9.33M -745K -729K -32.06M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
26-07-10 $0.1200 -4.00% 30,800
26-07-09 $0.1250 +4.17% 195,576
26-07-08 $0.1200 +4.35% 997,350
26-07-07 $0.1150 0.00% 32,162
26-07-06 $0.1150 -4.17% 217,325
  1. Stock Market
  2. Stocks
  3. AVCN Stock